Related Experiment Video
Updated: May 13, 2026
11:31
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
Trials in type 1 diabetes: Antigen-specific therapies
Ken T Coppieters1, Leonard C Harrison, Matthias G von Herrath
1Type 1 Diabetes R&D Center, Novo Nordisk Inc., Seattle, WA, USA.
Clinical Immunology (Orlando, Fla.)
|March 16, 2013
Summary
Type 1 diabetes (T1D) prevention requires balancing safety and efficacy. Antigen-specific tolerization offers a promising strategy to safely halt beta cell destruction and restore immune balance for long-term protection.
Area of Science:
- Immunology
- Endocrinology
- Autoimmune Diseases
Background:
- Type 1 diabetes (T1D) arises from immune attack on pancreatic beta cells.
- Current prevention strategies face challenges with safety and efficacy.
- Restoring immune balance is key to halting beta cell decay.
Purpose of the Study:
- To explore antigen-specific tolerization as a safe and effective T1D prevention strategy.
- To review clinical trial data and identify knowledge gaps.
- To discuss future directions for T1D prevention.
Main Methods:
- Review of existing clinical trial data on T1D prevention.
- Analysis of immune modulatory and immunosuppressive therapies.
- Conceptual outline of antigen-specific tolerization.
Main Results:
- Immunosuppressive agents show efficacy but pose safety risks.
- Immune modulatory drugs have yielded disappointing trial results.
- Antigen-specific tolerization presents a potential safe and lasting approach.
Conclusions:
- Balancing safety and efficacy is crucial for T1D prevention.
- Careful clinical trial design is paramount.
- Antigen-specific tolerization warrants further investigation for T1D prevention.
Related Concept Videos
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...